Vincent Sibaud

Toulouse, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 188 publications

Effectiveness and Safety of Apremilast in Immune Checkpoint Inhibitor-Associated Psoriasis: A Retrospective Multicenter Study From the EADV Task Force "Dermatology for Cancer Patients".

Effectiveness and Safety of Apremilast in Immune Checkpoint Inhibitor-Associated Psoriasis: A Retrospective Multicenter Study From the EADV Task Force "Dermatology for Cancer Patients".

Journal: International journal of dermatology

Published: June 04, 2026

Considering Body Mass Index for Skin Cancer Prevention Using Oral Nicotinamide.

Considering Body Mass Index for Skin Cancer Prevention Using Oral Nicotinamide.

Journal: Nutrition and cancer

Published: May 01, 2026

Optimized management of enfortumab vedotin-related dermatological toxicity.

Optimized management of enfortumab vedotin-related dermatological toxicity.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: April 06, 2026

Successful rechallenge of immune checkpoint inhibitor after immune-related myocarditis, myositis, myasthenia gravis overlap syndrome (IM3OS).

Successful rechallenge of immune checkpoint inhibitor after immune-related myocarditis, myositis, myasthenia gravis overlap syndrome (IM3OS).

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 31, 2026

Dermatologic Toxicities Induced by JAK Inhibitors.

Dermatologic Toxicities Induced by JAK Inhibitors.

Journal: American journal of clinical dermatology

Published: March 08, 2026

Corrective and Restorative Dermatology in Cancer Survivors: An Urgent Unmet Need!

Corrective and Restorative Dermatology in Cancer Survivors: An Urgent Unmet Need!

Journal: American journal of clinical dermatology

Published: January 22, 2026

Targeted therapies for psoriasis and atopic dermatitis in the context of malignancy: SPIN-FRT recommendations.

Targeted therapies for psoriasis and atopic dermatitis in the context of malignancy: SPIN-FRT recommendations.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: November 14, 2025

Dermatologic adverse events associated with amivantamab: A multicentre study.

Dermatologic adverse events associated with amivantamab: A multicentre study.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: November 05, 2025

Immune checkpoint inhibitor-induced eosinophilic fasciitis: A pharmacovigilance and EADV Task force study.

Immune checkpoint inhibitor-induced eosinophilic fasciitis: A pharmacovigilance and EADV Task force study.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: September 17, 2025

Update on dermatological toxicities of immune checkpoint inhibitors.

Update on dermatological toxicities of immune checkpoint inhibitors.

Journal: Presse medicale (Paris, France : 1983)

Published: September 08, 2025

Gamma secretase inhibitor nirogacestat and secondary hidradenitis suppurativa: An expected on-target effect.

Gamma secretase inhibitor nirogacestat and secondary hidradenitis suppurativa: An expected on-target effect.

Journal: Annales de dermatologie et de venereologie

Published: August 02, 2025

ALK inhibitor brigatinib-related photo-onycholysis.

ALK inhibitor brigatinib-related photo-onycholysis.

Journal: European journal of dermatology : EJD

Published: July 31, 2025

Showing 1-12 of 188

Last Updated: 09/26/2026